Neurometrix Inc (NURO)

$4.58 +0.22 (5.05%)
Market Cap 9.43M
Revenue (ttm) 3.03M
Net Income (ttm) -7.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -257.76%
Debt to Equity Ratio 0.00
Volume 35,500
Avg Vol 6,094
Day's Range N/A - N/A
Shares Out 2.06M
Stochastic %K 74%
Beta 1.00
Analysts Strong Buy
Price Target $50.00

Company Profile

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objec...

Industry: Medical Devices
Sector: Healthcare
Phone: 781 890 9989
Address:
4B Gill Street, Woburn, United States
Heywood_Jablomi
Heywood_Jablomi Jun. 5 at 1:48 PM
$NURO what the hell has happened here??
0 · Reply
nesanmano
nesanmano May. 22 at 7:45 PM
$NURO guys what is happening
1 · Reply
Elohim972
Elohim972 May. 19 at 8:10 PM
$NURO 💪👀
1 · Reply
BioTuesdays
BioTuesdays May. 2 at 1:59 PM
electroCore announced it has completed the merger with NeuroMetrix, expanding its portfolio to include Quell Fibromyalgia Solution, strengthening its commercial reach, and positioning the company as a diversified leader in non-invasive health and wellness solutions $ECOR $NURO https://biotuesdays.com/2025/05/02/electrocore-acquires-neurometrix-gaining-access-to-quell-platform/
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 2 at 12:36 PM
$NURO merger officially closed - shares converted to $4.49 cash + contingent value rights. Trading halted as stock delists. Final chapter for the once-promising neurotech play. Now it's all about execution on those Quell sales milestones through 2030. CVRs = lottery tickets with better odds than most biotechs. https://www.sec.gov/Archives/edgar/data/1289850/000164117225008179/form8-k.htm
0 · Reply
leosp11
leosp11 Mar. 31 at 9:06 PM
$NURO AI suggests buy here
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 7:05 PM
$NURO Quell tech looks promising. Digging into their fibromyalgia and CIPN potential. Might be an undervalued play in chronic pain management. FDA breakthrough designation gives some credibility. Watching closely for next moves in strategic review. great article: https://beyondspx.com/article/neurometrix-nuro-a-pioneering-medtech-navigating-challenges-in-chronic-pain-and-neuropathy-diagnostics
0 · Reply
PenkeTrading
PenkeTrading Mar. 25 at 12:06 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of NeuroMetrix Inc. Is that bullish or bearish? $NURO #NeuroMetrix #RsiOverbought #NASDAQ
0 · Reply
theshortsqueezer2022
theshortsqueezer2022 Mar. 24 at 9:29 PM
$TNON I missed out on $NURO in 2021 but this time I’m fully loaded
1 · Reply
theshortsqueezer2022
theshortsqueezer2022 Mar. 23 at 10:35 PM
$NURO buyout any time soon
0 · Reply
Latest News on NURO
NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO

Jan 6, 2025, 6:34 PM EST - 6 months ago

NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO

NeuroMetrix to be Acquired by electroCore

Dec 17, 2024, 4:05 PM EST - 7 months ago

NeuroMetrix to be Acquired by electroCore

NeuroMetrix Reiterates its Review of Strategic Alternatives

Aug 13, 2024, 2:47 PM EDT - 1 year ago

NeuroMetrix Reiterates its Review of Strategic Alternatives

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:33 AM EDT - 1 year ago

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

Jul 31, 2024, 2:03 PM EDT - 1 year ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

NeuroMetrix Reports Q1 2024 Business Highlights

May 15, 2024, 4:00 PM EDT - 1 year ago

NeuroMetrix Reports Q1 2024 Business Highlights

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

Apr 19, 2024, 8:00 AM EDT - 1 year ago

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

Mar 14, 2024, 9:00 AM EDT - 1 year ago

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Mar 13, 2024, 9:00 AM EDT - 1 year ago

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

Mar 4, 2024, 8:00 AM EST - 1 year ago

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 11:55 AM EST - 1 year ago

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Feb 22, 2024, 7:00 AM EST - 1 year ago

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

Feb 15, 2024, 9:00 AM EST - 1 year ago

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

Feb 13, 2024, 9:00 AM EST - 1 year ago

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

Jan 8, 2024, 9:43 AM EST - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

Dec 12, 2023, 9:00 AM EST - 1 year ago

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Dec 5, 2023, 9:00 AM EST - 1 year ago

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix Announces One-for-Eight Reverse Stock Split

Nov 20, 2023, 9:00 AM EST - 1 year ago

NeuroMetrix Announces One-for-Eight Reverse Stock Split

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

Oct 30, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript

Oct 27, 2023, 10:22 AM EDT - 1 year ago

NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript

NeuroMetrix Reports Q3 2023 Business Highlights

Oct 26, 2023, 7:00 AM EDT - 1 year ago

NeuroMetrix Reports Q3 2023 Business Highlights

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

Oct 23, 2023, 11:13 AM EDT - 1 year ago

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

Oct 2, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

Sep 28, 2023, 12:19 PM EDT - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

Aug 30, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

NeuroMetrix Reports Q2 2023 Business Highlights

Jul 27, 2023, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q2 2023 Business Highlights

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

Jul 20, 2023, 1:00 PM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

Jul 11, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

Jun 28, 2023, 9:00 AM EDT - 2 years ago

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

Jun 7, 2023, 9:00 AM EDT - 2 years ago

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

May 31, 2023, 9:00 AM EDT - 2 years ago

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Call Transcript

May 3, 2023, 12:41 PM EDT - 2 years ago

NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Call Transcript

NeuroMetrix Reports Q1 2023 Financial Results

May 3, 2023, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q1 2023 Financial Results

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

Apr 28, 2023, 9:21 AM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

Mar 21, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript

Feb 23, 2023, 5:23 PM EST - 2 years ago

NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

Feb 23, 2023, 7:00 AM EST - 2 years ago

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

Feb 16, 2023, 2:58 PM EST - 2 years ago

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Jan 23, 2023, 9:00 AM EST - 2 years ago

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

Nov 8, 2022, 9:00 AM EST - 2 years ago

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Call Transcript

Oct 20, 2022, 9:32 AM EDT - 2 years ago

NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Call Transcript

NeuroMetrix Reports Q3 2022 Financial Results

Oct 20, 2022, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q3 2022 Financial Results

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

Oct 12, 2022, 3:47 PM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23, 2022, 10:13 AM EDT - 3 years ago

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

Sep 1, 2022, 9:00 AM EDT - 3 years ago

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2022 Results - Earnings Call Transcript

Jul 21, 2022, 11:14 AM EDT - 3 years ago

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2022 Results - Earnings Call Transcript

NeuroMetrix Reports Q2 2022 Financial Results

Jul 21, 2022, 7:00 AM EDT - 3 years ago

NeuroMetrix Reports Q2 2022 Financial Results

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

Jul 14, 2022, 11:32 AM EDT - 3 years ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

Heywood_Jablomi
Heywood_Jablomi Jun. 5 at 1:48 PM
$NURO what the hell has happened here??
0 · Reply
nesanmano
nesanmano May. 22 at 7:45 PM
$NURO guys what is happening
1 · Reply
Elohim972
Elohim972 May. 19 at 8:10 PM
$NURO 💪👀
1 · Reply
BioTuesdays
BioTuesdays May. 2 at 1:59 PM
electroCore announced it has completed the merger with NeuroMetrix, expanding its portfolio to include Quell Fibromyalgia Solution, strengthening its commercial reach, and positioning the company as a diversified leader in non-invasive health and wellness solutions $ECOR $NURO https://biotuesdays.com/2025/05/02/electrocore-acquires-neurometrix-gaining-access-to-quell-platform/
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 2 at 12:36 PM
$NURO merger officially closed - shares converted to $4.49 cash + contingent value rights. Trading halted as stock delists. Final chapter for the once-promising neurotech play. Now it's all about execution on those Quell sales milestones through 2030. CVRs = lottery tickets with better odds than most biotechs. https://www.sec.gov/Archives/edgar/data/1289850/000164117225008179/form8-k.htm
0 · Reply
leosp11
leosp11 Mar. 31 at 9:06 PM
$NURO AI suggests buy here
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 7:05 PM
$NURO Quell tech looks promising. Digging into their fibromyalgia and CIPN potential. Might be an undervalued play in chronic pain management. FDA breakthrough designation gives some credibility. Watching closely for next moves in strategic review. great article: https://beyondspx.com/article/neurometrix-nuro-a-pioneering-medtech-navigating-challenges-in-chronic-pain-and-neuropathy-diagnostics
0 · Reply
PenkeTrading
PenkeTrading Mar. 25 at 12:06 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of NeuroMetrix Inc. Is that bullish or bearish? $NURO #NeuroMetrix #RsiOverbought #NASDAQ
0 · Reply
theshortsqueezer2022
theshortsqueezer2022 Mar. 24 at 9:29 PM
$TNON I missed out on $NURO in 2021 but this time I’m fully loaded
1 · Reply
theshortsqueezer2022
theshortsqueezer2022 Mar. 23 at 10:35 PM
$NURO buyout any time soon
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 26 at 4:21 AM
$NURO NeuroMetrix, Inc. (NASDAQ:NURO): Navigating Challenges and Exploring Strategic Alternatives https://beyondspx.com/article/neurometrix-nasdaq-nuro-a-pioneer-in-neurostimulation-and-diagnostics-navigating-a-shifting-market-landscape
0 · Reply
1factchecker
1factchecker Jan. 25 at 5:34 PM
$NURO
0 · Reply
ChartChartist
ChartChartist Jan. 4 at 9:58 PM
$AKAN sure it can go $NURO tight bands $SISI everyones bullish, nice $KUKE monday play idea, weekend fomo, eyes on it. For a quick trade
0 · Reply
Stock_Stuffer
Stock_Stuffer Jan. 4 at 4:25 PM
$NURO https://stockstuffer.com/reverse-stock-splits/
0 · Reply
1factchecker
1factchecker Dec. 20 at 1:41 AM
$NURO garbage
0 · Reply
risingstarsbynature
risingstarsbynature Dec. 19 at 4:34 AM
$NURO approximately $9M means around $5-$6 per share.
2 · Reply
brownant
brownant Dec. 18 at 3:53 PM
$NURO So anticlimactic with this piece of shit stock
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 18 at 12:19 PM
$NURO (+7.4% pre) electroCore $ECOR to Acquire NeuroMetrix (NURO) - SI https://ooc.bz/l/51172
0 · Reply
taxplanr
taxplanr Dec. 17 at 10:06 PM
$ECOR I already use the Truvaga for fibromyalgae. They are picking up FDA authorization for the price of $NURO inventory. Big score
2 · Reply
laste_rounde
laste_rounde Dec. 17 at 9:54 PM
$NURO Oddly enough I am a shareholder in ecor
0 · Reply
frontiere
frontiere Dec. 17 at 9:32 PM
$NURO NeuroMetrix acquired by $ECOR ElectroCore for an earn out cash over liabs at closing (tgt 2025-03-31) + CVR from DPNcheck platform (carve out) + royalties capped. ✅traded this small in August as a special event — that tussle w activist shareholders — bought 14 Aug $2.77-2.9, sold 21 Aug $3.52 all. Looks like not much missed. Neg EV like so many other biotechs in focus.
0 · Reply